Education
About Us
Working with TipRanks
Follow Us
Addex Therapeutics (ADXN)
NASDAQ:ADXN
Top Page
Addex Therapeutics
(NASDAQ:ADXN)
Rating:45Neutral
Price Target:―
Addex Therapeutics (ADXN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.74M
Dividend YieldN/A
Average Volume (3M)3.54K
Price to Earnings (P/E)0.9
Beta (1Y)0.16
Revenue Growth-70.05%
EPS GrowthN/A
CountryUS
Employees2
SectorHealthcare
Sector Strength55
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,536,287
10 Day Avg. Volume7,597
30 Day Avg. Volume3,536
Financial Highlights & Ratios
PEG Ratio-11.38
Price to Book (P/B)107.09
Price to Sales (P/S)0.00
P/FCF Ratio-32.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Addex Therapeutics Business Overview & Revenue Model
Company DescriptionAddex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
How the Company Makes MoneyAddex Therapeutics generates revenue primarily through strategic partnerships, collaborations, and licensing agreements with larger pharmaceutical companies. These partnerships often involve milestone payments, research funding, and royalties on sales of successfully developed drugs. The company may also benefit from government grants and research support for its scientific endeavors. Its business model relies on advancing its proprietary drug candidates through clinical trials to attract partnerships and potential acquisition interest from larger entities in the pharmaceutical industry.
Addex Therapeutics Earnings Call Summary
Earnings Call Date:Apr 25, 2025
(Q4-2024)
| % Change Since: 1.12%|
Next Earnings Date:Jun 02, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant strategic partnerships and advancements in drug development programs, notably the successful Series A financing for Neurosterix and progress in the GABAB PAM program. However, challenges remain with decreased income and cash limitations for unpartnered programs, indicating a balanced outlook.Q4-2024 Updates
Positive Updates
Successful Series A Financing
In 2024, the company launched Neurosterix with a US$65 million Series A financing led by Perceptive Advisors, securing financing for the platform and pre-clinical portfolio.
Partnership with Indivior
Partner Indivior selected a compound for development in substance use disorders, with Addex eligible for up to US$330 million in milestone payments and tiered royalties.
Progress in GABAB PAM Program
Completion of the R&D phase delivered multiple drug candidates. IND-enabling studies have started for substance use disorders.
Neurosterix Spin-out
Secured CHF5 million in cash and a 20% equity interest in Neurosterix, removing financing overhang.
Development of Dipraglurant
Repositioning dipraglurant for brain injury recovery with potential for enhancing rehabilitation impact.
Negative Updates
Decreased Income and R&D Expenses
Income decreased to CHF400,000 in 2024 from CHF1.6 million in 2023, primarily due to the completion of a research phase with Indivior. R&D expenses decreased by CHF0.2 million.
Cash Limitation for Unpartnered Programs
Current cash does not fund the progression of unpartnered programs into the clinic.
Dependence on Neurosterix
Significant reliance on Neurosterix for the continuation of certain programs, having divested major assets and staff.
Company Guidance
During the 2024 Full Year Financial Results Conference Call, Addex Therapeutics provided comprehensive guidance and updates on various programs and financial metrics. The company highlighted the launch of Neurosterix with a US$65 million Series A financing, alongside securing CHF5 million in cash and a 20% equity stake in Neurosterix. Addex reported making significant progress on its GABAB PAM program, with partner Indivior selecting a drug candidate for substance use disorders and initiating R&D studies. The company is eligible for up to US$330 million in milestone payments and tiered royalties. Addex also emphasized the advancement of its independent GABAB PAM program for chronic cough, aiming to start IND-enabling studies this year. Financially, the company ended 2024 with CHF3.3 million in cash, expecting it to sustain operations until mid-2026. The Neurosterix transaction was noted to have reduced cash burn and secured CHF5 million for Addex, with strategic emphasis on leveraging its 20% interest in Neurosterix for future clinical advancements.Addex Therapeutics Financial Statement Overview
Summary
Addex Therapeutics is facing significant financial challenges, including declining revenues, negative profitability, and cash flow issues. Despite a low debt-to-equity ratio, the company relies heavily on financing activities to maintain operations, highlighting the need for strategic improvements in revenue growth and operational efficiencies.Income Statement
Addex Therapeutics has experienced declining revenues with negative growth over the years. The company shows negative gross profit margins, indicating high costs relative to revenues. Net profit margin is also negative, reflecting ongoing profitability challenges. EBIT and EBITDA margins are unfavorable, highlighting operational inefficiencies.30
Negative
Balance Sheet
The balance sheet reveals a low debt-to-equity ratio, indicating minimal leverage, which is positive. However, the company has consistently reported negative net income, leading to poor return on equity. The equity ratio remains strong, suggesting a solid asset base relative to liabilities.40
Negative
Cash Flow
Cash flow analysis shows negative free cash flow, which is concerning for liquidity. The operating cash flow to net income ratio is negative, indicating operational cash flow challenges. Financing activities have been required to support cash flow needs, pointing to reliance on external funding.35
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 557.48K | 1.61M | 1.42M | 2.92M | 3.61M | 2.76M | Gross Profit |
| -988.78K | -5.32M | -13.20M | -9.90M | -6.76M | 2.53M | EBIT |
| -4.99M | -10.28M | -20.52M | -15.51M | -12.24M | -14.83M | EBITDA |
| -6.37M | -10.23M | -20.23M | -14.94M | -12.41M | -14.32M | Net Income Common Stockholders |
| 5.40M | -10.56M | -20.80M | -15.35M | -12.86M | -14.78M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 3.35M | 3.87M | 6.96M | 20.50M | 18.76M | 31.55M | Total Assets |
| 12.17M | 4.64M | 8.28M | 22.54M | 20.18M | 33.03M | Total Debt |
| 43.77K | 344.34K | 373.13K | 482.01K | 567.40K | 550.25K | Net Debt |
| -3.31M | -3.52M | -6.58M | -20.00M | -18.13M | -30.99M | Total Liabilities |
| 1.11M | 3.50M | 3.37M | 5.61M | 5.57M | 7.50M | Stockholders Equity |
| 11.06M | 1.15M | 4.91M | 16.93M | 14.61M | 25.52M |
| Cash Flow | Free Cash Flow | ||||
| -5.97M | -8.00M | -16.44M | -14.74M | -12.24M | -9.51M | Operating Cash Flow |
| -5.97M | -7.99M | -16.44M | -14.71M | -12.18M | -9.48M | Investing Cash Flow |
| 4.66M | -6.84K | 2.97K | -30.31K | -59.41K | -43.25K | Financing Cash Flow |
| 47.02K | 5.26M | 3.10M | 16.40M | 46.40K | -463.69K |
Addex Therapeutics Technical Analysis
Negative
8.11
Price Trends
7.95
Positive
7.82
Positive
8.54
Negative
Market Momentum
0.25
Negative
47.52
Neutral
19.22
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADXN, the sentiment is Negative. The current price of 8.11 is below the 20-day moving average (MA) of 8.44, above the 50-day MA of 7.95, and below the 200-day MA of 8.54, indicating a neutral trend. The MACD of 0.25 indicates Negative momentum. The RSI at 47.52 is Neutral, neither overbought nor oversold. The STOCH value of 19.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ADXN.
Addex Therapeutics Risk Analysis
Addex Therapeutics disclosed 54 risk factors in its most recent earnings report. Addex Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Addex Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $5.38B | 3.31 | -45.11% | 3.29% | 16.82% | 0.04% | |
45 Neutral | $13.74M | 0.88 | -92.60% | ― | -70.05% | ― | |
41 Neutral | $11.42M | ― | 249.03% | ― | -14.43% | 16.04% | |
| $148.27M | ― | -2264.31% | ― | ― | ― | ||
44 Neutral | $9.74M | ― | -214.79% | ― | ― | 52.82% | |
34 Underperform | $12.10M | 2.16 | >-0.01% | ― | ― | ― | |
34 Underperform | $17.32M | ― | -616.17% | ― | ― | 71.39% |
* Healthcare Sector Average
Performance Comparison
ADXN
Addex Therapeutics
8.38
0.39
4.88%
PSTV
Plus Therapeutics
0.31
-1.69
-84.50%
ERNA
Eterna Therapeutics
2.29
-27.26
-92.25%
NERV
Minerva Neurosciences
1.80
-1.85
-50.68%
GOVX
GeoVax Labs
1.03
-0.08
-7.21%
MBRX
Moleculin Biotech
0.64
-3.30
-83.76%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.